Brand-name comparison · reviewed October 1st, 2026
Zepbound and Wegovy are the two best-known brand-name GLP-1 medicines for weight management. This guide sets their FDA labels side by side, then shows how to ask about either one online.
Zepbound uses tirzepatide, which acts on two gut-hormone receptors. Wegovy uses semaglutide, which acts on one, and it also comes as a daily tablet. Gallup's 2026 poll found 11% of U.S. adults currently take a GLP-1 for weight loss, nearly four times the 2024 rate, so many people are asking this question.
From the prescribing information
Every row comes from the current FDA labels. Dosing is not covered here because your prescriber sets it.
| Topic | Zepbound | Wegovy |
|---|---|---|
| Active Ingredient | Tirzepatide, which activates both the GIP and GLP-1 receptors | Semaglutide, which activates the GLP-1 receptor |
| Maker | Eli Lilly and Company | Novo Nordisk |
| Forms on the FDA Label | Injection only: single-dose pens, single-dose vials, multi-dose vials, and KwikPen | Injection (prefilled) and a daily tablet |
| How Often | Once-weekly injection | Once-weekly injection, or a once-daily tablet |
| Weight Management Use | Weight reduction and long-term maintenance in adults with obesity, or overweight with a weight-related condition | Weight reduction and long-term maintenance in adults with obesity, or overweight with a weight-related condition. The injection label also includes patients 12 and older with obesity |
| Other Labeled Uses | Moderate to severe obstructive sleep apnea in adults with obesity | Reducing major cardiovascular events in adults with established heart disease and obesity or overweight. The injection also has an accelerated-approval indication for MASH (a fatty liver disease) with moderate to advanced fibrosis |
| Boxed Warning | Risk of thyroid C-cell tumors | Risk of thyroid C-cell tumors |
| Common Reactions (5% or More) | Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, belching, hair loss, reflux | Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, gas, reflux, and others listed on the label |
Our GLP-1 pills guide covers the Wegovy tablet and Foundayo, a once-daily oral option from Eli Lilly.
Choosing With a Clinician
None of these settle the question alone. They are the topics a good intake covers.
Both labels list thyroid cancer history (medullary thyroid carcinoma) and Multiple Endocrine Neoplasia syndrome type 2 as contraindications. Other conditions, medicines, and pregnancy plans also matter, and only a clinician can weigh them.
The labeled uses differ. Zepbound lists obstructive sleep apnea. Wegovy lists cardiovascular risk reduction and, for the injection, MASH. If one of these applies to you, mention it at intake.
Wegovy is available as a weekly injection or a daily tablet. Zepbound is a weekly injection. Comfort with injections and daily routines are fair things to discuss with your prescriber.
Plans vary on which brand they cover and whether prior authorization is required. Ask each program what you would pay with and without coverage, and what is billed separately from the medicine.
Product availability and pharmacy options change. Confirm the product, the dispensing pharmacy, and shipping terms for your state before you pay.
Telehealth Path
The process is the same as for any GLP-1: intake, clinician review, a licensed pharmacy, and follow-up. See the full prescription workflow.
Some telehealth programs publish brand-name medicines and handle insurance paperwork. Membership and medication are often billed separately, so compare both. For direct-pay options, see our tirzepatide and semaglutide provider rankings, and cash costs without insurance.
See Ro Body Pricing and Options See Hims Weight Loss Options
Zepbound and Wegovy Questions
Eligibility, product choice, and dosing belong to your clinician.
Zepbound contains tirzepatide, which acts on both GIP and GLP-1 receptors, and is a once-weekly injection. Wegovy contains semaglutide, which acts on the GLP-1 receptor, and comes as a once-weekly injection or a once-daily tablet. Their FDA-labeled uses also differ beyond weight management.
Neither label says one is better for everyone. The right choice depends on your health history, other conditions, medicines, coverage, and preferences, so it is a decision for you and a licensed clinician.
A licensed clinician can evaluate you through telehealth and prescribe either medicine when it is legally permitted and medically appropriate. An online intake never guarantees a prescription. See our guide to getting a GLP-1 prescription online.
No. FDA states that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality. Ask any program exactly which product and pharmacy you would receive.
No. Both labels say using the product with another GLP-1 receptor agonist is not recommended, and Zepbound also advises against other tirzepatide products. Follow your clinician's instructions.
It depends on your plan, the labeled use, and plan rules such as prior authorization. Some online programs help with coverage checks. Ask for the cash price too, because coverage is never guaranteed.
Primary Sources
FDA labels and government guidance behind the drug facts on this page.